Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.

ABSTRACT:

Aims

The 2018 ESC/ESH guidelines for hypertension recommend differential management of patients who are <65, 65-79, and ≥80 years of age. However, it is unclear whether intensive blood pressure lowering is well-tolerated and modifies risk uniformly across the age spectrum.

Methods and results

SPRINT randomized 9361 high-risk adults without diabetes and age ≥50 years with systolic blood pressure 130-180 mmHg to either intensive or standard antihypertensive treatment. The primary efficacy endpoint was the composite of acute coronary syndromes, stroke, heart failure, or death from cardiovascular causes. The primary safety endpoint was composite serious adverse events. We assessed whether age modified the efficacy and safety of intensive vs. standard blood pressure lowering usin

SUBMITTER: Byrne C 

PROVIDER: S-EPMC7669324 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature